| Objective: To explore the clinical significance of the expression of p53 and p16 in diffuse large B-cell lymphoma. Methods: The expression of p53 and p16 in 61 patients with diffuse large B-cell lymphoma (DLBCL) was analyzed by using immunohis- tochemical staining (EnVision). Meanwhile,Pearson'sχ2 test was used to determine if there was any relationship between the expression of p53 and p16 and immunological phenotype, Ann arbor clinical stage, IPI score and other clinical features of DLBCL. SPSS 13.0 was used for all statistical analyses. Results: Among 61 cases of DLBCL,the expression rates of p53 and p16 were 40.0% (25/61) and 13.1% (8/61), respectively (2) The expression of p53 in DLBCL significantly correlated with Ann arbor clinical stage,but not with the patients'age, gender, nation, immunological phenotype and IPI score. Aberrant expression of p53 was more frequent in high stage (â…¢,â…£), compared with in low stage (â… ,â…¡), (P=0.032). And when 61 patients with DLBCL was classified into GC and NGC phenotype according to the immunohistochemical expression of CD10, BCL6 and MUM1, the relationship between p53 and Ann arbor clinical stage was remained in the NGC phenotype, but the same relationship was not exist in GC phenotype. (3)While,the absence of p16 showed no significant correlation with the patients'age, gender, nation, immunological phenotype, Ann arbor clinical stage and IPI score. Conclusions: 1) The two immunological phenotype of DLBCL significantly correlated with prognosis, it may become a pattern of predicting prognosis. 2) The high expression of p53 might play an important role in deciding the malignancy degree and prognosis in NGCB-DLBCL; However, the same contribution of p53 has not been confirmed in GCB-DLBCL. The hypothesis need be idendtified. 3) Taken together (the high expression of p53 and the absence of p16),it was suggested that p53 could offer a useful reference in clinical proceeding, malignancy degree and predicting of DLBCL. |